Cancer Cure Here All Along?

Cancer
In a Congressional Committee Hearing in 1996, Sgt. Rick Schiff of the San Francisco Police Department, who holds the highest Medal of Honor for bravery, told the chilling tale of the death of his daughter and the soon-to-be death of her identical twin sister. Schiff spoke out that day, against the government’s opposition of, through organizations like the FDA and The Medical Board, the use of an experimental cancer treatment. Schiff knew that some people did not want the truth to be released to the public—that the cure for cancer had been here all along.

In 1967, Dr. Stanislaw Burzynski had begun his journey of curing cancer that would ultimately change medicine forever, but not before bringing about an astonishing truth. Burzynski began his career at the age of only 24, when he obtained his M.D. at the top of his class, from the Medical Academy in Lublin, Poland. That same year, he made a discovery that medical professionals have been seeking for a very long time. Burzynski had stumbled upon a strain of peptides normally found in human blood and urine that play a deciding factor in whether or not a person has cancer.

The following year, Burzynski obtained his Ph.D. in biochemistry and further studied his new findings. From 1970 to 1977, while working as a researcher and Assistant Professor at Baylor College of Medicine in Houston, TX, Burzynski’s research was sponsored and partially funded by the National Cancer Institute. All along the way, Burzynski had made major advancements here in his cure for cancer.

Cancer cells are already within the body, usually in a dormant state. However, Burzynski discovered that people who lack these peptides usually have activated cancer cells and those who have plenty of these peptides do not. The human body contains two categories of genes that allow cancer to grow–Oncogenes and Tumor Suppressor genes. In people who have cancer, a higher level of their Oncogenes are “switched on” and a higher level of their Tumor Suppressor genes are “switched off.”

After discovering this, Burzynski found a way to extract the peptides from healthy human blood and urine and created his own formula called antineoplastons. Antineoplastons target the specific genes that allow cancer to flourish, working on almost 100 different gene types. The true benefit of these antineoplastons lies in the fact that some patients do not need to remain on them for the rest of their lives, because they eventually cure the body of cancer permanently.

Burzynski put his discovery to good use by opening up his own clinic in 1977 and offering people suffering from numerous types of cancer, even terminal, his cure and a second chance at life. Dr. Burzynski has since treated over 8,000 patients with cancer at his clinic in Houston, Texas. Despite his best efforts, the Texas State Board of Medical Examiners would attempt to intervene, ensuring that many other people suffering with cancer would unfortunately die before knowing that the cure had been here all along.

In 1986, the Texas State Board of Medical Examiners requested that Dr. Burzynski submit proof that his treatments did not harm any of his patients, which he did. In 1988, the board finally responded to Burzynski’s research submission by claiming that he was violating a fictitious law and threatened to revoke his medical license. In 1990, then again, in 1992, the board continued to file complaints against the doctor for reasons that were not plausible. After some time, 60 of Dr. Burzynski’s patients eventually petitioned that the board leave him alone and allow him to continue to research as well as treat people with cancer.

Eventually, in 1993, this case went to trial, where Judge Earl Corbitt ruled in the favor of Dr. Burzynski, stating that his cure and methods for administering it were safe and effective. Since it was later discovered that the FDA was in fact pressuring the Texas Medical Board to pursue these court cases, upon failing yet again, the FDA eventually stepped up the fight against Burzynski. In an effort to ensure their success, the FDA raided the Burzynski Clinic several times and confiscated all of his patients medical records, which were essential to aiding him in successfully curing these patients.

Dr. Burzynski had continued to fight the FDA, in hopes of stopping them from shutting down his clinic and ending his research. The FDA, which acts as practically a “gatekeeper” to the pharmaceutical companies, received backhanded fees of over half a billion dollars annually from them, worked relentlessly trying to suppress Burzynski’s cure for cancer. After numerous court hearings and despite their repeated attempts, due to public and Congressional pressure, the FDA had no choice but to accept and approve Dr. Burzynski’s cure.

In a recent article on Oct. 24, 2014, it stated that the FDA gave the Burzynski Research Institute permission to conduct an open trial administering the latest version of their antineoplastons in patients under the age of three, who suffer from a brain tumor known as diffuse intrinsic brainstem glioma (DIBG).

There is no doubt that there may be forces in this world that try to control and limit certain things that may potentially better the public in the name of greed. However, it is Dr. Burzynski’s, as well as many others, belief that the pharmaceutical companies, through the FDA, have been trying to stop his research and treatments in fear of a future where people no longer need medication in the form of their products. Thus, allowing Burzynski to commandeer all of the profits. For those who are still skeptical about a cure for most cancers being here all along, it is highly recommended that they watch the documentary Burzynski, which is available for free via YouTube and in the link below.

Opinion By Robert Masucci

Sources:
Burzynski, The Movie
The Burzynski Clinic
USA Today–Burzynski Trial Reopens
USA Today–Who Is Stanislaw Burzynski
National Cancer Institute
FDA Burzynski Documents
Interview with Sgt. Rick Schiff 2012
Gnomes National News
The Cancer Industry (book)
Photo by SbrandnerGNU License